↓ Skip to main content

First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma

Overview of attention for article published in Cancer Discovery, November 2023
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
14 news outlets
blogs
1 blog
twitter
22 X users
wikipedia
1 Wikipedia page

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
3 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma
Published in
Cancer Discovery, November 2023
DOI 10.1158/2159-8290.cd-23-0670
Pubmed ID
Authors

Jennifer A. Woyach, Deborah M. Stephens, Ian W. Flinn, Seema A. Bhat, Ronald E. Savage, Feng Chai, Sudharshan Eathiraj, Sean D. Reiff, Elizabeth M. Muhowski, Lindsey Granlund, Lyndsey Szuszkiewicz, Wayne Wang, Brian Schwartz, Razi Ghori, Mohammed Z.H. Farooqui, John C. Byrd

X Demographics

X Demographics

The data shown below were collected from the profiles of 22 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 3 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 3 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 1 33%
Unknown 2 67%
Readers by discipline Count As %
Unspecified 1 33%
Unknown 2 67%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 117. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 January 2024.
All research outputs
#354,348
of 25,269,846 outputs
Outputs from Cancer Discovery
#171
of 4,036 outputs
Outputs of similar age
#5,939
of 349,586 outputs
Outputs of similar age from Cancer Discovery
#4
of 89 outputs
Altmetric has tracked 25,269,846 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,036 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.5. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 349,586 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 89 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.